Prototypical Stressors

Showing 126 to 150 of 777 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

166	Benzoic acid, 4-chloro-, 2-benzoyl-2-(1,1-dimethylethyl)hydrazide		None
427	Beta-carboline		None
543	beta-Sitosterol	beta-Sitosterol, CAS-RN: 83-46-5, DTXSID5022481	None
210	Bezafibrate	Bezafibrate, CAS-RN: 41859-67-0, DTXSID3029869	37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents
580	Bicalutamide	Bicalutamide, CAS-RN: 90357-06-5, DTXSID2022678	None
107	Bifenthrin	Bifenthrin, CAS-RN: 82657-04-3, DTXSID9020160	None
474	BIO (6-bromoindirubin-3’-oxime)		410: GSK3beta inactivation leading to increased mortality via defects in developing inner ear
279	Bioflavonoids		202: Inhibitor binding to topoisomerase II leading to infant leukaemia
11	Bis(2-ethylhexyl) phthalate	Di(2-ethylhexyl) phthalate, CAS-RN: 117-81-7, DTXSID5020607	2 AOPs 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 307: Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring
665	Bis(2,4,6-trimethylphenyl)-lambda~2~-germane--selenium (1/1)	Bis(2,4,6-trimethylphenyl)-lambda~2~-germane--selenium (1/1), CAS-RN: 115385-04-1, DTXSID10556604	413: Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure
467	Bisdiamine		2 AOPs 297: Inhibition of retinaldehyde dehydrogenase leads to population decline 436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
521	Bisphenol A	Bisphenol A, CAS-RN: 80-05-7, DTXSID7020182	2 AOPs 314: Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) 522: Estrogen antagonism leading to increased risk of autism-like behavior
337	Bleomycin	Bleomycin, CAS-RN: 11056-06-7, DTXSID1030862	173: Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis
428	BMS 345541	BMS 345541, CAS-RN: 547757-23-3, DTXSID70203243	None
726	BMS-89453		436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
138	Bromocriptine	Bromocriptine, CAS-RN: 25614-03-3, DTXSID1022687	None
12	Butyl 4-hydroxybenzoate	4-Hydroxybenzoic acid butyl ester, CAS-RN: 94-26-8, DTXSID3020209	None
568	butyl benzyl phthalate		None
687	Butylate	Butylate, CAS-RN: 2008-41-5, DTXSID7023936	None
561	Butylparaben	4-Hydroxybenzoic acid butyl ester, CAS-RN: 94-26-8, DTXSID3020209	None
341	Butyrate	Butyrate, CAS-RN: 461-55-2, DTXSID8040432	2 AOPs 212: Histone deacetylase inhibition leading to testicular atrophy 274: Histone deacetylase inhibition leads to impeded craniofacial development
775	C.I. Acid Blue 62		None
335	Cadmium	Cadmium, CAS-RN: 7440-43-9, DTXSID1023940	4 AOPs 257: Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity 499: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis 521: Essential element imbalance leads to reproductive failure via oxidative stress
456	Cadmium chloride	Cadmium chloride, CAS-RN: 10108-64-2, DTXSID6020226	296: Oxidative DNA damage leading to chromosomal aberrations and mutations
380	Calcium channel blockers		261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility